GENB

Generate Biomedicines, Inc. NASDAQ

Financial Services ·Asset Management ·US · generatebiomedicines.com

$13.15

Mkt Cap $658.7M

52w Low $11.00 49.8% of range 52w High $15.32

50d MA $12.34 200d MA $12.34

P/E (TTM) -2.6x

EV/EBITDA -2.8x

P/B —

Debt/Equity -0.1x

ROE —

P/FCF -3.1x

RSI (14) —

ATR (14) —

Beta 0.00

50d MA $12.34

200d MA $12.34

Avg Volume 632.8K

About

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is i…

Recent Filings

8-K

Generate Biomedicines, Inc. -- 8-K Filing

Generate Biomedicines' amended and restated certificate of incorporation and bylaws became effective upon the company's registration statement effectiveness, updating its corporate governance structure.

Mar 2

Data updated apr 25, 2026 11:09am · Source: massive.com